Malignant Mesothelioma of Peritoneum

Promising feasibility study results for imaging technology that identified malignant peritoneal tumor metastasis during surgery NEWTON, Mass.--(BUSINESS WIRE)-- Lumicell Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced promising initial data from its ongoing feasibility study for lead candidate LUMISIGHT™ to detect peritoneal malignancies during surgical debulking. The ongoing study is utilizing the investigational LUMISIGHT optical imaging drug and accompanying imaging device to distinguish tumor metastases to organs within the peritoneum. The initial results from adult patients were shared in a podium presentation by James C. Cusack, Jr. MD, Associate Professor of Surgery at Massachusetts General Hospital, at the Advanced Cancer Therapies meeting organized by the Society of Surgical Oncology. “This data advances the potential for image-guided surgery to detect small tumors and metastases to organs in the peritoneal cavity which could provide better outcomes for our patients,” said Dr. Cusack. “Further innovation is desperately needed to improve the benefits of cytoreductive surgery for this invasive and elusive cancer. We look forward to continuing the clinical development program with Lumicell and advancing patient care.” The presence of peritoneal metastases has a significant negative impact on survival for patients. One of the most important determinants of treatment success and long-term overall survival is the ability to achieve removal of all visible cancer during initial surgery prior to the heated chemotherapy for a complete cytoreduction.2-5 “We are highly encouraged by this initial data in a promising new indication, as we continue to expand the development of LUMISIGHT across the spectrum of solid tumors. Everything we do at Lumicell is focused on improving surgical outcomes for patients,” said Howard Hechler, President of Lumicell. About Peritoneal Surface Malignancies and Metastasis Peritoneal surface malignancies include primary peritoneal malignant mesothelioma and tumors that have spread from different organs, referred to as peritoneal metastases. These metastases can originate from organs such as appendiceal, colorectal, gastric, pancreatic, and ovarian cancers, and affect more than 75,000 patients each year in the United States.1 The presence of disease and the extent of disease are often difficult to be fully evaluated by conventional non-invasive imaging techniques such as CT scan, PET scan, or MRI. Small peritoneal surface nodules are often detected at the time of surgical exploration by the surgeon’s eyes versus conventional imaging techniques. One of the most important determinants of treatment success and overall survival is the ability to achieve complete cytoreduction (CCR).2-5 While patients with no residual disease (CCR0) or minimal residual peritoneal surface tumor nodules less than 2.5 mm in maximum diameter (CCR1) have significantly better survival than those with residual nodules more than 2.5 mm in maximum diameter (CCR2), patients with CCR0 have experienced the best clinical outcomes.2,3,5 About Lumicell, Inc. Lumicell is a privately held company focused on the development and commercialization of innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs. The company’s first products pending approval are LUMISIGHT™ and the Lumicell™ Direct Visualization System which, in combination, are designed to illuminate cancerous tissue during initial surgery potentially reducing the frequency of repeat surgeries. LUMISIGHT and the Lumicell Direct Visualization System are investigational products, both limited by federal law to investigational use only and are not commercially available. These products are currently under FDA review for their first indication in breast conserving surgery; and are also being explored across a wide variety of solid tumor indications to enhance the standard of care treatment by guiding the resection of additional cancer that may have otherwise been left behind. For more information, please visit or follow us at LinkedIn and X. Foster, J.M., Zhang, C., Rehman, S., Sharma, P. and Alexander, H.R. (2023), The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. CA A Cancer J Clin, 73: 49-71. Elias, D., F. Quenet, and D. Goere, Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma. Surg Oncol Clin N Am, 2012. 21(4): p. 611-23. Glockzin, G. and P. Piso, Current status and future directions in gastric cancer with peritoneal dissemination. Surg Oncol Clin N Am, 2012. 21(4): p. 625-33. Helm, C.W., Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am, 2012. 21(4): p. 645-63. Votanopoulos, K.I., et al., Current status and future directions in appendiceal cancer with peritoneal dissemination. Surg Oncol Clin N Am, 2012. 21(4): p. 599-609. Chan, C.H., et al., Preclinical Evaluation of Cathepsin-Based Fluorescent Imaging System for Cytoreductive Surgery. Ann Surg Oncol, 2017. 24(4): p. 931-938.

YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on February 4, has announced three major developments that will further the global fight against cancer and forge new paths in tumor treatments. The Company not only endeavors to contribute to the field of anti-cancer treatments, but also provide much-improved medical opportunities and increased hope to all patients. Dr. Jianmin Fang, CEO of RemeGen, commented, "Cancer is the common enemy of mankind, and at RemeGen we feel a strong sense of responsibility and mission to continue to provide more effective and safer treatment options for cancer patients around the world through our cutting-edge innovation and research. On World Cancer Day 2024, we are proud to announce more advances in cancer drug research through drug discovery and collaboration with our partners. We are celebrating the progress of scientific research and working for a more just and healthier future. Our time is now, and our mission is clear. Let's act together for a world without cancers." RemeGen's three major recent developments On January 12, RemeGen announced that it enrolled its first patient on a Phase II study of Disitamab Vedotin combined with Zimberelimab to treat cervical cancer patients who have failed at least one first-line platinum-containing standard treatment. Preliminary data show that Disitamab Vedotin can significantly improve treatment efficiency and its safety is controllable. Zimberelimab, compared with the data of PD-1/PD-L1 single drugs approved for this indication (not head-to-head), displayed excellent long-term efficacy with a higher objective response rate (ORR) of 27.8%, a median progression-free survival (mPFS) of 3.7 months, a median overall survival (mOS) of 16.8 months, and a 2-year duration of response (DoR) rate of 55%. This study is a new combination treatment strategy that is expected to provide better options for cervical cancer patients and bring new hope. On January 15, RemeGen announced its RC88 combined with Sintilimab injection to treat advanced malignant entities in cooperation with Innovent Biologics was approved by the State Food and Drug Administration's for Center for Drug Evaluation (CDE). The Phase I/IIa clinical study in tumor patients approved by the CDE is an open, multi-center Phase I/IIa clinical study in patients with advanced malignant solid tumors expressing mesothelin (MSLN). It includes, but is not limited to, pleural mesothelioma, peritoneal mesothelioma, ovarian cancer, pancreatic cancer, and lung adenocarcinoma, gastric adenocarcinoma, triple-negative breast cancer, among other cancer types that may benefit to evaluate the efficacy, safety, tolerability, PK characteristics, immunogenicity, and preliminary results of RC88 combined with Sintilimab injection administered every three weeks. Also recently, a national multi-center clinical study of RemeGen's Disitamab Vedotin (RC48) combined with monoclonal antibody, Toripalimab, in the treatment of HER2-expressing advanced gastric cancer and other solid tumors, led by Professor Shen Lin from Peking University Cancer Hospital, was published in The Lancet sub-journal eClinicalMedicine. This study is the first to explore the safety and efficacy of antibody drug conjugates (ADC) combined with immunotherapy in patients with HER2-positive and HER2-low-expressing gastric cancer. The study results show that Disitamab Vedotin combined with Toripalimab has a controllable safety profile and is effective in patients with HER2-positive and HER2-low-expressing gastric cancer or gastroesophageal junction (G/GEJ) cancer, displaying encouraging efficacy. About World Cancer Day World Cancer Day is a leading international awareness day held every February 4 and is the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness, improving education and catalyzing personal, collective and government action, organizers all work together to reimagine a world where millions of preventable cancer deaths are saved and access to life-saving cancer treatment and care is equitable for all - no matter who you are or where you live. About RemeGen Co. Ltd. Founded in 2008, RemeGen (9995.HK, SHA: 688331) is a leading biopharmaceutical company in China committed to providing solutions to the unmet clinical needs of patients suffering from life-threatening illnesses. RemeGen has research laboratories and offices throughout China and the United States. The company is committed to discovering, developing, and commercializing innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology, and ophthalmic diseases. For more details, please visit: SOURCE RemeGen Co., Ltd

Abdominal Cancers Alliance to provide education and resources to patients, families and physicians surrounding abdominal cancers and CRS/HIPEC procedure BALTIMORE (September 25, 2023) Partners for Cancer Care and Prevention (PFCCAP), a 501(c)(3) public health nonprofit, today announced the launch of their newest program, the Abdominal Cancers Alliance. International in scope but led by renowned Baltimore-based surgical oncologist Dr. Armando Sardi, the Abdominal Cancers Alliance is a central education hub providing resources and accurate, updated information to patients and families about abdominal cancers and the Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) procedure, an aggressive treatment for a variety of intra-abdominal malignancies in advanced stages. The success of this approach is significant with data showing 10- and even 20-year survival. Even with these promising results and over 3,000 publications worldwide on CRS/HIPEC, most patients are still referred late. “We give hope to those with late-stage abdominal cancers and provide options and resources for treatment,” said Armando Sardi, M.D., FACS, president & founder of Partners for Cancer Care and Prevention. “CRS/HIPEC is a treatment option for a variety of gynecological and gastrointestinal malignancies. Early referral to treatment is key to improving survival and a potential cure. After nearly 30 years of being in this space, we’ve understood the patient journey well and see that there is a series of needs from education on the front end to care on the back end of treatment, and that is why we are launching the Abdominal Cancers Alliance.” The Abdominal Cancers Alliance, a patient-led organization, assists patients in getting the proper information regarding their cancer treatment in a timely manner and connects them with organizations, other patients, and the medical community, to provide lifesaving treatments. As the central hub, the Abdominal Cancers Alliance will focus on these core initiatives: Establish a central information system of resources on abdominal cancers and treatment options such as CRS/HIPEC. Educate the public and medical community about the importance of early diagnosis and proper treatment of abdominal cancers. Advocate for patients and families, helping them navigate through a promising journey. Advance and promote the work of existing organizations already making an impact. The CRS/HIPEC procedures involve the removal of visible tumors from the abdominal area combined with a heated chemotherapy solution added to the abdominal cavity to destroy non-visible tumor cells that may remain after surgery. CRS/HIPEC is a treatment option for cancers including appendix, colon and rectal, gastric and stomach, ovarian, fallopian tube, uterine, Peritoneal Mesothelioma, Primary Peritoneal Cancer, Pseudomyxoma Peritonei (PMP), and several others. In addition to leading PFCCAP and the Abdominal Cancers Alliance, Dr. Sardi serves as the Director of The Institute for Cancer Care at Mercy Medical Center in Baltimore’s Surgical Oncology Division. He is an internationally renowned surgeon and one of the foremost surgical oncologists in the United States using CRS/HIPEC. Dr. Sardi is a National Cancer Institute Clinical Investigator and is committed to conducting vital research. As of early 2023, the medical team including Dr. Sardi and his medical partner Dr. Vadim Gushchin, have performed more than 1,000 successful CRS/HIPEC procedures. In addition to their work in Baltimore, the procedure is being done in various hospitals across the US and in several countries worldwide. It has been the subject of thousands of published journal articles with information detailing how successful this treatment can be for treating late-stage cancer. Despite the volume of data and over 35 years of successful use, CRS/HIPEC is still not a widely known and utilized treatment option by the medical community. ### About Partners for Cancer Care and Prevention: Established in 2011 by Dr. Armando Sardi, MD, FACS, Dr. Ruth Singer, MD, and Dr. John Singer, MD, Partners for Cancer Care and Prevention is bridging the gap in cancer care by assembling a network of people and organizations that make better treatment a reality, improving the outcomes for patients and families. Its mission is to advocate for cancer patients by making connections, providing education, and guiding patient navigation to improve the quality and length of their life, with a focus on breast, cervical, and abdominal cancers. Partners for Cancer Care and Prevention’s programs in North and South America continue to significantly increase patients’ chances of long-term survival, potential cure, and increased quality of life. For more information, please visit . CONTACTS: Eric Hammond | Maroon PR | 443-614-9456 | Eric@MaroonPR.com Madison McGovern | Maroon PR | 202-430-1753 | Madison@MaroonPR.com Tyler Horton | PFCCAP | 317-471-7593 | thorton@pfccap.org